Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reissued by Wells Fargo & Co in a research report issued to clients and investors on Monday.
VRX has been the topic of a number of other research reports. Deutsche Bank set a $20.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “hold” rating in a research report on Wednesday, February 21st. ValuEngine raised Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. TD Securities lifted their target price on Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Goldman Sachs Group initiated coverage on Valeant Pharmaceuticals Intl in a research report on Wednesday, January 24th. They issued a “sell” rating and a $18.00 target price on the stock. Finally, HC Wainwright set a $24.00 target price on Valeant Pharmaceuticals Intl and gave the company a “hold” rating in a research report on Tuesday, January 16th. Seven analysts have rated the stock with a sell rating, ten have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $18.30.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at $16.08 on Monday. The company has a market capitalization of $5,600.00, a PE ratio of 3.95, a PEG ratio of 0.52 and a beta of -0.28. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25. Valeant Pharmaceuticals Intl has a 1 year low of $8.31 and a 1 year high of $24.43.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, March 8th. The stock was bought at an average cost of $15.34 per share, for a total transaction of $153,400.00. Following the purchase, the director now owns 106,062 shares of the company’s stock, valued at approximately $1,626,991.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph C. Papa bought 30,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Tuesday, March 13th. The shares were acquired at an average price of $16.05 per share, with a total value of $481,500.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 7,121,629 shares of company stock worth $109,702,487 in the last ninety days. Insiders own 5.87% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of VRX. Prime Capital Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth approximately $142,000. Sheaff Brock Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth approximately $200,000. Cetera Investment Advisers bought a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth approximately $208,000. Keybank National Association OH bought a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth approximately $208,000. Finally, Traynor Capital Management Inc. bought a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth approximately $213,000. Institutional investors own 50.12% of the company’s stock.
WARNING: “Valeant Pharmaceuticals Intl (VRX) Given “Sell” Rating at Wells Fargo & Co” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.themarketsdaily.com/2018/03/14/valeant-pharmaceuticals-intl-vrx-given-sell-rating-at-wells-fargo-co.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.